NCT00315549终止3 期
Multinational, Randomized, Double Blind, Comparative Study to Evaluate the Efficacy and Safety of 5 Days Telithromycin 800 mg od Versus 10 Days Penicillin V 500 mg Tid in Adolescent and Adult Subjects Equal to or Over 13 Years With Streptococcus Pyogenes Tonsillitis/Pharyngitis
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 终止
- 发起方
- Sanofi
- 入组人数
- 233
- 试验地点
- 5
- 主要终点
- To compare the bacteriologic efficacy of 5-days of telithromycin to 10-days of penicillin V insubjects at the posttherapy/test-of-cure (TOC) visit in the per protocol population.
研究概览
简要总结
This is a multinational, randomized (1:1), double blind, comparator-controlled, 2 parallel treatment group study in subjects equal to or over 13 years of age, with Streptococcus pyogenes tonsillitis/pharyngitis (T/P). Each subject will receive either telithromycin, 400 mg over-encapsulated tablets, 800 mg once daily for 5 days or penicillin V 250 mg over-encapsulated tablets, 500 mg three times daily for 10days. Matching placebo capsules will be dispensed to maintain the blind between the treatment groups.A positive rapid identification test for streptococcal Group A antigen will be required for all subjects at Visit 1 (Day 1) for entry into the study. Throat swab specimens for bacterial culture, identification, and antibiotic-susceptibility testing will be taken at Visits 1, 3 and 4.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 13 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age equal to or over 13 years;
- •For female subjects, the following conditions are to be met:
- •Subject is premenarchal or surgically incapable of bearing children,
- •Subject is of childbearing potential and all of the following conditions are met:
- •Have normal menstrual flow within 1 month before study entry,
- •Have negative pregnancy test (urine pregnancy test sensitive to at least 50 mU/mL, and
- •Must agree to use an accepted method of contraception throughout the study (if sexually active);
- •Clinical diagnosis of acute tonsillitis/pharyngitis caused by Streptococcus pyogenes based on:
- •A positive result from a rapid detection test for Group A streptococcal antigen and submission of a throat swab specimen for bacterial culture, identification, and antibiotic-susceptibility testing; and
- •A sore and scratchy throat and/or pain on swallowing (odynophagia) together with at least 2 of the following clinical signs:
- •Tonsil and/or pharyngeal erythema and/or exudate;
- •Cervical adenopathy;
- •Uvular edema;
排除标准
- •Symptoms that collectively suggest nonstreptococcal T/P (eg, laryngitis, coryza, conjunctivitis, diarrhea, cough);
- •History of positive throat culture for Streptococcus pyogenes in the absence of clinical signs and symptoms of T/P;
- •Infection of the deep tissues of the upper respiratory tract (eg, epiglottitis, retropharyngeal or buccal cellulitis, or abscess of the retropharynx, tonsil, or peritonsillar area) or of the suprapharyngeal respiratory tract and its connecting structures (eg, sinusitis, otitis media, or orbital/periorbital cellulitis);
- •History of rheumatic heart disease;
- •Known congenital prolonged QT syndrome;
- •Known or suspected uncorrected hypokalemia (≤3 mmol/L [mEq/L) or hypomagnesemia or bradycardia (<50 bpm);
- •Known impaired renal function, as shown by creatinine clearance ≤25 mL/min
- •Myasthenia gravis;
- •History of hypersensitivity or intolerance to macrolides, penicillins, or cephalosporins;
- •Previous enrollment in this study or previous treatment with telithromycin;
- •Children of the investigator or subinvestigator, research assistant, pharmacist, study coordinator, other staff, or relative thereof directly involved in the conduct of the protocol.
- •Is currently being treated with systemic antibacterials or has been treated with systemic antibacterials within 14 days prior to enrollment;
- •Has been treated with any investigational medication within the last 30 days;
- •Has been treated with rifampicin, phenytoin, carbamazepine, or St. John's wort within the last 2 weeks.
结局指标
主要结局
To compare the bacteriologic efficacy of 5-days of telithromycin to 10-days of penicillin V insubjects at the posttherapy/test-of-cure (TOC) visit in the per protocol population.
次要结局
- To compare the bacteriologic efficacy of 5-days of telithromycin to 10-days of penicillin V insubjects at the posttherapy/test-of-cure (TOC) visit andlate posttherapy visit (Visit 4) in the bacteriologic modified intent to treat population.
研究者
研究点 (5)
Loading locations...
相似试验
终止
3 期
TELI COM - Telithromycin in Children With Otitis MediaOtitis Media, SuppurativeOtitis Media, PurulentNCT00315003Sanofi1,500
终止
3 期
TELI TON - Telithromycin in TonsillitisTonsillitisPharyngitisNCT00315042Sanofi314
终止
3 期
Efficacy and Safety Study of Benralizumab in Patient With Eosinophilic Chronic Rhinosinusitis With Nasal Polyps (ORCHID)NCT04157335AstraZeneca295
已完成
2 期
A Study of Plazomicin Compared With Levofloxacin for the Treatment of Complicated Urinary Tract Infection (cUTI) and Acute Pyelonephritis (AP)Acute PyelonephritisComplicated Urinary Tract InfectionNCT01096849Achaogen, Inc.145
已完成
3 期
A Study to Compare Efficacy, PK, PD, Safety and IMM of MB09 to Prolia® [EU-sourced] in Postmenopausal Osteoporosis.Postmenopausal Women With OsteoporosisNCT05338086mAbxience Research S.L.558